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Abstract
BACKGROUND AND OBJECTIVE—New Jersey was the first state to implement legislatively 
mandated newborn pulse oximetry screening (POxS) in all licensed birthing facilities to detect 
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critical congenital heart defects (CCHDs). The objective of this report was to evaluate 
implementation of New Jersey’s statewide POxS mandate.
METHODS—A 2-pronged approach was used to collect data on infants screened in all New 
Jersey birthing facilities from August 31, 2011, through May 31, 2012. Aggregate screening 
results were submitted by each birthing facility. Data on failed screens and clinical characteristics 
of those newborns were reported to the New Jersey Birth Defects Registry (NJBDR). Three 
indicators were used to distinguish the added value of mandated POxS from standard clinical care: 
prenatal congenital heart defect diagnosis, cardiology consultation or echocardiogram indicated or 
performed before PoxS, or clinical findings at the time of POxS warranting a pulse oximetry 
measurement.
RESULTS—Of 75 324 live births in licensed New Jersey birthing facilities, 73 320 were eligible 
for screening, of which 99% were screened. Forty-nine infants with failed POxS were reported to 
the NJBDR, 30 of whom had diagnostic evaluations solely attributable to the mandated screening. 
Three of the 30 infants had previously unsuspected CCHDs and 17 had other diagnoses or non-
CCHD echocardiogram findings.
CONCLUSIONS—In the first 9 months after implementation, New Jersey achieved a high 
statewide screening rate and established surveillance mechanisms to evaluate the unique 
contribution of POxS. The screening mandate identified 3 infants with previously unsuspected 
CCHDs that otherwise might have resulted in significant morbidity and mortality and also 
identified other significant secondary targets such as sepsis and pneumonia.
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Approximately 2 per 1000 live births in the United States are infants born with critical 
congenital heart defects (CCHDs), of which an estimated 20% are neither diagnosed 
prenatally nor identified by clinical examination before hospital discharge, with wide 
variation by specific type of CCHD.1–3 New Jersey was the first state to implement 
legislatively mandated newborn pulse oximetry screening (POxS) to improve early detection 
of CCHDs. Legislation signed into law on June 2, 2011, and implemented 90 days later on 
August 31, requires all licensed birthing facilities to “perform a pulse oximetry screening a 
minimum of 24 hours after birth, on every newborn in its care.”4 This requirement applies to 
all live births regardless of health status, prenatal diagnosis of CCHDs, or location (eg, 
NICU/special care nursery [SCN], well-baby nursery [WBN]). To facilitate implementation 
of the screening requirement, the New Jersey Department of Health (NJDOH) convened a 
working group that developed a recommended screening algorithm that specified screening 
in both the right hand and either foot between 24 and 48 hours of life or when medically 
appropriate after 24 hours of age (Appendix 1). In all cases it is recommended for screening 
to be done before discharge. The NJDOH also developed an approach using surveillance 
mechanisms to evaluate the POxS program.
In September 2011, the US Secretary of Health and Human Services recommended that all 
states incorporate screening for CCHDs into their newborn screening panel.5 At least 35 
states have passed or introduced legislation to mandate this screening.6 We present the first 
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9 months of screening experience in New Jersey, including screening rates and case 
detection, to highlight the benefits, challenges, and issues for consideration that might help 
guide implementation in other states.
METHODS
Defining CCHD
We defined CCHD to include those defects that usually cause hypoxemia (ie, hypoplastic 
left heart syndrome, pulmonary atresia, Tetralogy of Fallot, total anomalous pulmonary 
venous return, transposition of great arteries, tricuspid atresia, truncus arteriosus) and those 
significant defects that sometimes, but less consistently, cause hypoxemia (ie, coarctation of 
aorta, double outlet right ventricle, single ventricle, interrupted aortic arch, Ebstein 
anomaly).1,7
Data Sources
Screening Data Collection—All birthing facilities (52 facilities in operation before 
October 2011 and 53 after that date) submit aggregate data on a quarterly basis to the 
NJDOH, which includes the number of live births, the number screened, and the number of 
failed screening results. For purposes of this evaluation, the term “live births” refers to all 
infants born alive at the 53 licensed birthing facilities in New Jersey. A standard form is 
used to collect these data and to facilitate consistent reporting, including information about 
newborns who were not screened (eg, transfers, deaths, missed for unknown reasons) 
(Appendix 2). This report reflects the first 9 months after POxS implementation (August 31, 
2011, to May 31, 2012).
New Jersey Birth Defects Registry—Health care professionals are required by law to 
report infants with CCHDs who are New Jersey residents to the New Jersey Birth Defects 
Registry (NJBDR) as soon as possible after diagnosis.8 As a result of the mandate, the 
NJBDR was expanded to monitor failed POxS. With the use of a new diagnostic code for 
failed POxS, all birthing facilities were requested to report individual-level data on infants’ 
failed POxS results, regardless of presence of CCHDs, to the NJBDR. This report includes 
the time of birth, screening results, findings from the diagnostic evaluation (eg, 
echocardiogram), any relevant prenatal diagnoses, and other clinical characteristics such as 
whether the infant was asymptomatic at the time of screening. For failed screens, the 
NJBDR staff investigated cases in which the information was unclear or if a CCHD was 
identified as a result of mandated POxS. The NJBDR staff also investigated registered cases 
of CCHDs that had no accompanying report of failed POxS to the NJBDR.
Assessment of the Impact of the Screening Mandate
Aggregate reports were submitted every 3 months and were used to determine overall 
screening coverage. To determine the proportion of eligible live births who were screened, 
we excluded those live births who were not screened because they died before screening, 
were not medically appropriate to have been screened (eg, receiving oxygen in the NICU), 
were <24 hours old at the end of the reporting period, or were transferred to another hospital 
before 24 hours of age. To avoid possible double counting, we also excluded (1) live births 
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who were not screened and transferred out of a hospital after 24 hours of age from the total 
live-birth count (Fig 1, Appendix 2) and (2) live births who were screened and transferred 
into a New Jersey birthing facility at anytime during the reporting period from the number of 
reported screens (Appendix 2).
The NJBDR was used to determine outcomes for those with a failed screen and to monitor 
CCHD cases. Three clinical indicators were used to determine whether the diagnostic 
evaluation was solely attributable to POxS or whether it would otherwise have occurred in 
the absence of the POxS mandate. These indicators included a prenatal diagnosis of 
congenital heart defects (CHDs), whether a cardiology consultation or echocardiogram was 
indicated or performed before screening on the basis of clinical factors (eg, maternal history, 
signs of CHD), or whether there were clinical findings at the time of the screen that would 
have otherwise warranted a pulse oximetry measurement.
Data Analysis
χ2 Tests of significance were used to examine differences in the proportions of missed 
screens over the three, 3-month aggregate data reporting periods.
This project was determined by the NJDOH Institutional Review Board to be public health 
practice.
RESULTS
Over the 9-month study period, 75 324 live births were reported from the licensed birthing 
facilities in New Jersey, of whom 97.3% (n = 73 320) were eligible for screening (Fig 1). Of 
those eligible to be screened, 99.1% underwent POxS. The proportion of missed screens 
decreased substantially over the study period from 1.8% in the first period to 0.2% in the 
third period (P < .001). Ninety-seven infants were reported to the NJBDR with a failed 
POxS, CCHD, or both.
Infants With Failed POxS Reported to the NJBDR
Forty-nine infants were reported to the NJBDR with a failed POxS (Fig 2). Thirty of the 49 
infants (61%) with a failed POxS had none of the 3 clinical indicators and therefore their 
diagnostic evaluation was solely attributable to their failed screen. Of these 30 infants, 3 had 
CCHDs that otherwise might have resulted in serious morbidity or mortality if diagnosis had 
been delayed in the absence of screening. All 3 infants were in the WBN at the time of the 
screen, none had a prenatal diagnosis of CHD or a cardiac consult or echocardiogram 
indicated before the POxS, and none had clinical signs present at the time of the POxS that 
would have otherwise warranted a pulse oximetry measurement (Table 1). Seventeen of the 
30 infants who received a diagnostic evaluation as a result of a failed POxS had other 
diagnoses, including culture-negative sepsis, pneumonia, pulmonary hypertension, other 
types of CHDs (eg, ventricular septal defect) or other echocardiogram findings (eg, patent 
formen ovale or patent ductus arteriosis). Ten of the 30 infants had no cardiac abnormalities 
found on echo-cardiogram, and no other diagnoses were made on the basis of the available 
follow-up information (Fig 2, Table 1).
Garg et al. Page 4













The remaining 19 infants with a failed POxS had 1 of the 3 clinical indicators, suggesting 
that the mandated POxS would not have changed the already indicated evaluation and 
subsequent clinical management of these infants (Fig 2). Therefore, their diagnostic 
evaluation was not solely attributable to the mandated POxS. Four of these infants had 
CCHDs (transposition of the great arteries, hypoplastic left heart syndrome, total anomalous 
pulmonary venous return, interrupted aortic arch). Of the remaining 15, 13 had other forms 
of CHDs or echocardiogram findings (eg, bicuspid aortic valve, patent formen ovale, patent 
ductus arteriosis) or other noncardiac diagnoses (eg, pneumothorax), and 2 reportedly had 
no diagnosis made.
Infants With CCHDs but No Failed POxS Reported to the NJBDR
Forty-eight infants were reported to the NJBDR with CCHDs without an accompanying 
failed POxS reported to the registry (Table 2). These infants had 3 identified reasons for not 
having an accompanying failed POxS registered. The infants could have (1) passed the 
POxS, (2) failed the POxS without being reported, or (3) might not have been screened. 
Based on available clinical information, at least 98% of these infants with CCHDs but no 
accompanying failed POxS registered, experienced ≥1 of the following: a prenatal CHD 
diagnosis, transfer out of the birthing hospital within 1 day of life, clinical monitoring with 
pulse oximetry in the NICU/SCN, or passing POxS results.
DISCUSSION
This article represents the first published report in the United States from a legislatively 
mandated, statewide POxS program for all live hospital births. In the first 9 months after the 
New Jersey mandate, ~73 000 infants were screened, leading to the identification of 3 
infants with previously unsuspected CCHDs. Consistent with findings from other studies, 
New Jersey’s POxS program identified several newborns with other potentially important 
and unsuspected conditions or CHDs.2,9–13 Similar to other time-sensitive biochemical 
newborn screening tests for related metabolic and endocrine disorders, our findings support 
that POxS can improve the timing of diagnosis of and intervention for CCHDs. Although 
our findings address the clinical utility of POxS, information on related costs and resource 
use for statewide POxS implementation is limited. Recent data from a random sample of 
New Jersey hospitals indicate that the estimated costs of POxS per newborn ($14) is lower 
than that for laboratory metabolic screening ($20) and hospital-based hearing screening 
($36–$39, adjusted to 2011 dollars).14–16 However, these estimates do not include costs 
incurred from follow-up diagnostic evaluations and/or medical intervention as a result of the 
failed POxS. Our data indicated that the number of echocardiograms conducted as a result of 
failed mandatory POxS for infants with no subsequent potentially significant findings was 
only 7 over this 9-month period. In addition, it does not appear that resources for 
transferring infants who failed the POxS were used unnecessarily because at least 5 of the 6 
infants whose transfers were triggered solely by the failed POxS had potentially significant 
echocardiogram findings. Importantly, many of the infants who failed the mandatory screen 
had previous clinical history or signs that would have triggered a subsequent diagnostic 
evaluation regardless of the statewide mandate, hence requiring no additional resources. 
Although we do not know how many of the 48 infants with CCHDs without a registered 
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failed screen would have actually failed the POxS, for most of these infants, the mandated 
POxS likely would not have caused additional resource use beyond that which was already 
clinically indicated.
Implementing and evaluating statewide POxS necessitated a bridging of traditional newborn 
screening and birth defects surveillance perspectives. Because most previous studies 
assessing POxS excluded symptomatic and/or prenatally diagnosed infants,2,9–11,13,17–19 
there was no existing approach for implementing and/or evaluating the POxS for all live 
births, including infants in the NICU and those prenatally diagnosed with CCHDs. Within 
90 days of the signing of the legislative mandate, the NJDOH developed a recommended 
screening algorithm, and the POxS mandate was implemented for all live births in all New 
Jersey birthing hospitals with 94% of WBNs and 88% of NICU/SCNs reporting to have 
adopted the algorithm specifically recommended by the NJDOH. Data from a recent 
investigation in New Jersey revealed that the addition of the new mandated screening 
processes posed minimal burden on hospital nursing staff.20
From the New Jersey experience, it is clear that to evaluate the added value of a statewide 
POxS mandate, establishing mechanisms or using existing systems for surveillance is 
necessary. In New Jersey, as is possible in other states, there was no feasible, immediate 
mechanism (eg, bloodspot card or electronic birth certificate) to quickly incorporate 
individual-level screening results and details on infants’ clinical characteristics into a 
statewide, systematic reporting system. Results from New Jersey’s universal newborn 
hearing screening program, another statewide point-of-care screening program, are captured 
within NJDOH’s electronic birth certificate. At the time of implementation of POxS, the 
electronic birth certificate was being reengineered and was not modifiable statewide in all 
birthing facilities. The introduction of aggregate screening data reports and individual-level 
reporting of failed screens to the NJBDR enabled us to quickly capture data to evaluate our 
statewide mandate. We found that providing a prescriptive template for the aggregate data 
reporting request was quite useful in obtaining consistent reports across all 53 birthing 
facilities. Understanding the discrepancies between the number of live births and number of 
infants screened enabled us to adjust the proportion of live births screened to more 
accurately reflect infants eligible to be screened. Therefore, we believe the aggregate-level 
data provide us with a close approximation of implementation coverage. The planned 
implementation of a new statewide electronic birth reporting system will enable us to collect 
individual-level data and therefore provide a more accurate reconciliation of infants 
transferred. Use of the NJBDR to collect detailed relevant clinical characteristics (eg, 
whether CHD was prenatally detected, a cardiac consult was indicated before the POxS, 
and/or clinical signs were present at the time of the POxS) of infants who failed the POxS 
was crucial to evaluate the unique contribution of POxS. As such, we anticipate that the 
NJBDR will continue to be a necessary tool for collection of detailed information on infants 
with failed POxS.
Our data collection efforts suggested that some degree of underreporting may have occurred. 
In particular, the identification of 48 infants with CCHDs without a registered failed POxS 
revealed that pulse oximetry was not consistently used or reported as a screening tool. With 
high relevance to implementation of a statewide mandate, these findings underscore that 
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training and education are needed to emphasize that all infants are required to receive the 
mandated POxS regardless of their location in the hospital or prenatal diagnosis and any 
infant that fails the screening protocol should be reported to the NJBDR. Our findings also 
highlight the need to clarify and emphasize the distinction between the use of pulse oximetry 
as part of a diagnostic assessment and its use as a universal screening tool. These potential 
sources of underreporting of failed screens appear to be most relevant to NICU/SCN infants 
or those with preexisting diagnoses or symptoms rather than those in the WBN. In addition, 
the NJDOH received reports of several infants whose failed screens were erroneously 
deemed a “pass” by hospital staff. This further highlights the need for significant and 
ongoing education, outreach, and technical support for health care providers and nursery 
staff. Performing audits to determine the extent of underreporting at the hospital level is an 
essential part of future quality assurance activities as is encouraging hospitals to establish 
their own internal audit protocols. Quality assurance and training efforts in New Jersey need 
to also focus on POxS techniques (eg, sensor placement) and interpretation of results to 
assess and ensure the validity of POxS implementation.
The New Jersey experience produced meaningful qualitative and quantitative information 
for evaluating and improving our program as well as for assisting other states as they begin 
implementation and evaluation of POxS. Nevertheless, generalization of our observed 
number of infants with failed POxS and/or CCHDs to what other states might expect should 
be done with consideration of a few limitations. The lower number of infants with CCHDs 
and/or failed POxS in New Jersey, compared with other studies,10,11 is likely attributable to 
several factors, with prenatal detection being a major consideration.21 Given the close 
geographic proximity to major out-of-state pediatric cardiac surgical centers, New Jersey 
resident mothers of infants with prenatally diagnosed CCHDs may choose to deliver in a 
neighboring state. In addition, infants receiving care exclusively out of state are not 
routinely reported to the NJBDR. Although the overall proportion of New Jersey resident 
infants with CCHDs prenatally diagnosed is not known, the estimate may be higher than the 
36% to 50% previously reported1,11 due to the increased use of ultrasounds in routine 
prenatal care22 as well as the significant training efforts23 in parts of New Jersey. A higher 
prenatal detection rate coupled with the possibility of infants with prenatally detected 
CCHDs being born and solely receiving care out of state could result in an underestimation 
of CCHD cases and infants with reported failed POxS in the NJBDR. Although this report is 
well beyond the average time from birth to the age of registration in the NJBDR (~50 days), 
it is still possible that additional infants with CCHDs may be reported to the NJBDR due to 
late diagnosis or late reporting.24 Other potential sources of underascertainment include 
providers not screening infants, providers not reporting infants with a failed POxS, and 
exclusion of infants born in New Jersey to mothers who were residents of another state. 
Historically, the NJBDR has only included infants born to New Jersey residents, although it 
has recently been modified to accommodate registration of failed POxS for out-of-state 
residents born in New Jersey.
The NJDOH’s approach and data collection mechanisms used to evaluate the statewide 
POxS mandate may provide insight and guidance to other states implementing or 
considering similar legislation. Despite the challenges of a short implementation period and 
being first in the nation to implement statewide POxS, the NJDOH was able to implement a 
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statewide screening effort with a reported high coverage rate, a means to track the 
proportion of the population screened, and a mechanism by which to obtain relevant clinical 
information on those infants with a failed POxS. As other states plan and evaluate their 
POxS programs, we encourage consideration of a number of factors including obtaining 
information on clinical indicators, exploring the role of prenatal diagnosis, and assessing the 
ability of surveillance systems to ascertain all failed screens and CCHD cases born in and/or 
to residents of the state.25 National efforts are currently underway to develop standardized 
protocols and minimal core data sets and to facilitate sharing of information between states 
with the ultimate goal of creating more efficient and effective programs to improve the 
health of infants. From a statewide experience, the results from the first 9 months in New 
Jersey revealed that mandated POxS successfully identified 3 infants with previously 
undetected CCHDs who likely would have been discharged from the hospital in the absence 
of a failed POxS, potentially resulting in significant morbidity or death.
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APPENDIX 1. New Jersey Department of Health’s recommended pulse 
oximetry screening algorithm used during the study period. Subsequent to 
the study period, the initial algorithm shown above was updated.26
APPENDIX 2. Aggregate Data–Reporting Template
Date of reporting period:
Hospital name:
Total
1 Number of live births born at birthing facility during current reporting perioda
2 Number of live births screened with pulse oximetry during current reporting perioda
3 Number of failed screens
Explanation of live births screened and not screened in current reporting period
 Live births who were screened at your birthing facility in current reporting period
(a) Number born and screened at your birthing facility in current reporting period
(b) Number born at your birthing facility in previous reporting period, but screened in current 
reporting period
(c) Number not born at your birthing facility, but transferred into your birthing facility and screened 
in current reporting period
–Name(s) of hospital(s) transferred from and number of infants transferred
(d) Other explanation(s), provide number of infants for each explanation:
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Date of reporting period:
Hospital name:
Total
 Live births born at your birthing facility during current reporting period who were not screened in current 
reporting period
(e) Number of expirations
(f) Number not medically appropriate to screen
(g) Number born at birthing facility, but <24 hours of age at end of current reporting period
(h) Number transferred out of your birthing facility at <24 hours
–Name(s) of hospital(s) transferred to and number of infants transferred
(i) Number transferred out of your birthing facility at ≥24 hours
–Name(s) of hospital(s) transferred to and number of infants transferred
(j) Other explanation(s), provide number of infants for each explanation:
Definitions for data items above:
(1) Number of infants in the WBN and NICU/SCN who were born at your birthing facility during the current reporting 
period. This number does not represent all admissions (ie, excludes those transferred into your facility).
(2) Number of infants screened at your birthing facility during the current reporting period. This number includes infants 
born at your facility and those transferred into your facility who were screened.
(3) Number of infants who failed the pulse oximetry screening at your birthing facility in the current reporting period.
(a) Number of infants both born and screened at your birthing facility during the current reporting period.
(b) Number of infants born at your birthing facility during the previous reporting period, but who were screened in the 
current reporting period. This number is likely to represent infants who were previously medically unstable or too young to 
be screened in the previous reporting period.
(c) Number of infants not born at your birthing facility but who were transferred into your birthing facility and screened 
during the current reporting period. Below list the name of the hospital the infant was transferred from. If transfers were 
received from multiple hospitals, create a row for each hospital. Include the number of infants who were admitted.
(d) Explanation of why an infant was screened in the current reporting period, if not listed above (eg, home births).
(e) Number of infants born at your birthing facility during the current reporting period that expired before conducting the 
pulse oximetry screening.
(f) Number of infants born at your birthing facility during the current reporting period who were not medically appropriate 
for pulse oximetry screening. This number is primarily applicable to NICU infants.
(g) Number of infants born at your birthing facility during the current reporting period who were <24 hours of age at the 
end of the current reporting period and were therefore were not screened during the current reporting period.
(h) Number of infants born at your birthing facility during the current reporting period who were not screened and were 
transferred out at <24 hours. Below list the name of the hospital the infant was transferred to. If infants were transferred to 
different hospitals, create a row for each hospital. Include the number of infants who were transferred.
(i) Number of infants born at your birthing facility during the current reporting period who were not screened and were 
transferred out of your birthing facility at ≥24 hours. Below list the name of the hospital the infant was transferred to. If 
infants were transferred to different hospitals, create a row for each hospital. Include the number of infants who were 
transferred.
(j) Explanation of why an infant was not screened, if not listed (eg, discharged, 24 hours, parents refused screen, etc).
a
Important: Infants who were in both the WBN and the NICU or SCN during the current reporting period should only be 
counted once for all reporting items above.
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WHAT’S KNOWN ON THIS SUBJECT
Prenatal diagnosis and clinical examination do not identify all infants with critical 
congenital heart defects before hospital discharge. To improve early critical congenital 
heart defect detection, New Jersey was the first state to implement legislatively mandated 
newborn pulse oximetry screening.
WHAT THIS STUDY ADDS
This report is the first to evaluate statewide pulse oximetry screening implementation. 
New Jersey had a high statewide screening rate and identified 3 infants with previously 
unsuspected critical congenital heart defects that otherwise might have resulted in 
significant morbidity and mortality.
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Aggregate pulse oximetry screening results from all licensed New Jersey birthing facilities 
for live births from August 31, 2011, to May 31, 2012. aReported reason for having not been 
screened. NJ, New Jersey.
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Failed pulse oximetry screens reported to the New Jersey Birth Defects Registry for New 
Jersey–resident live births screened from August 31, 2011, to May 31, 2012.
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TABLE 2
Number of Children With CCHDs Reported to the New Jersey Birth Defects Registry Without Failed POxS
Type of CCHD n (Total N = 48)
Tetralogy of Fallot 15
Coarctation of aorta 13
Transposition of great arteries 4
Double outlet right ventricle 2
Hypoplastic left heart syndrome and coarctation of aorta 2




Hypoplastic left heart syndrome and single ventricle 1
Tetralogy of Fallot and pulmonary atresia 1
Transposition of great arteries and single ventricle 1
Tricuspid atresia 1
Tricuspid atresia, pulmonary atresia, and TAPVR 1
Data represent New Jersey resident live births from August 31, 2011 to May 31, 2012. TAPVR, total anomalous pulmonary venous return.
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